Pneumonia - Market Insight, Epidemiology, and Market Forecast - 2036

Key Highlights:

• In the United States, the annual incidence of community-acquired pneumonia (CAP) is estimated at approximately 24.8 cases per 10,000 adults, with rates increasing significantly with advancing age.
• Pneumonia is an acute respiratory infection that affects the air sacs (alveoli) in one or both lungs.
• Some of the US FDA approved drugs for the treatment of pneumonia include XACDURO (sulbactam + durlobactam), ZEVTERA (ceftobiprole medocaril), and others.
• Pipeline drugs for pneumonia, such as tosatoxumab (AR-301), CAL02, AON-D21 (anti-C5a), and others are advancing the treatment landscape with novel targeted approaches.

DelveInsight's "Pneumonia Market Insights, Epidemiology, and Market Forecast-2036" report delivers an in-depth understanding of the Pneumonia, historical and forecasted epidemiology as well as the Pneumonia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Pneumonia market report provides current treatment practices, emerging drugs, Pneumonia market share of the individual therapies, current and forecasted Pneumonia market Size from 2022 to 2036 segmented by seven major markets. The Report also covers current Pneumonia treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Pneumonia market.

Geography Covered:

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2022-2036

Pneumonia Treatment Algorithm and Disease Understanding

Pneumonia is an acute respiratory infection that affects the air sacs (alveoli) in one or both lungs. These air sacs may fill with fluid or pus, causing symptoms such as cough, fever, chills, and difficulty breathing. It can be caused by bacteria, viruses, fungi, or aspiration and ranges from mild to life-threatening, especially in young children, older adults, and immunocompromised individuals.

Pneumonia Diagnosis

Diagnosis is based on medical history, physical examination, and investigations. Abnormal breath sounds such as crackles may be heard on examination. A chest X-ray is commonly used to confirm lung involvement, while blood tests, sputum cultures, and pulse oximetry help assess severity and identify the cause.

Pneumonia Treatment

In the US, the Infectious Diseases Society of America (IDSA) and the American Thoracic Society (ATS) recommend risk-stratified empiric antibiotic therapy for CAP, typically combining a B-lactam with a macrolide or using a respiratory fluoroquinolone in appropriate patients. In Europe, guidance from the European Respiratory Society supports similar severity-based treatment pathways, while Germany and France follow national adaptations aligned with European standards. In the UK, the National Institute for Health and Care Excellence (NICE) recommends prompt antibiotic initiation guided by clinical severity scores such as CURB-65. In Japan, the Japanese Respiratory Society provides detailed recommendations for CAP and HAP, including pathogen-directed therapy and antimicrobial stewardship principles.

Management of severe pneumonia typically requires hospitalization and may include intravenous broad-spectrum antibiotics, oxygen supplementation, and supportive care.

Pneumonia Epidemiology

The Pneumonia epidemiology section provides insights about the historical and current Pneumonia patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Pneumonia market report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Pneumonia epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2022 to 2036.

• In the United States, the annual incidence of community-acquired pneumonia (CAP) is estimated at approximately 24.8 cases per 10,000 adults, with rates increasing significantly with advancing age. Incidence varies across populations and is influenced by factors such as seasonality, geographic differences, and underlying comorbid conditions.
• Hospital-acquired pneumonia is associated with a significant risk of mortality, with ventilator-associated pneumonia reporting all-cause mortality rates of 20-50%. Factors linked to higher mortality include severity of illness at diagnosis (e.g., shock, coma, respiratory failure, ARDS), bacteremia, and underlying comorbidities, emphasizing the need for timely recognition and appropriate management.
• In a US multicenter study of pneumonia patients, a pathogen was identified in 38% of cases, including viruses in 23%, bacteria in 11%, mixed bacterial-viral infections in 3%, and fungal or mycobacterial pathogens in 1%, with human rhinovirus (9%), influenza virus (6%), and Streptococcus pneumoniae (5%) being the most commonly detected organisms.

Pneumonia Drug Chapters

The drug chapter segment of the Pneumonia report encloses the detailed analysis of Pneumonia marketed drugs and late-stage (Phase-III and Phase-II) Pneumonia pipeline drugs. It also helps to understand the Pneumonia clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Pneumonia Marketed Drugs

ZEVTERA: Basilea Pharmaceutica/Innoviva Specialty Therapeutics

ZEVTERA (ceftobiprole medocaril sodium) is an advanced-generation cephalosporin antibiotic originally developed by Basilea Pharmaceutica and, in the US, marketed through licensing by Innoviva Specialty Therapeutics. It works by binding to penicillin-binding proteins (PBPs), including PBP2a, and inhibiting bacterial cell wall synthesis, with broad activity against Gram-positive bacteria (including MRSA) and certain Gram-negative organisms. ZEVTERA received US FDA approval in April 2024 for the treatment of community-acquired bacterial pneumonia (CABP) in adults and pediatric patients (3 months to <18 years) as well as for HABP/VABP in adults.

XACDURO: Innoviva Specialty Therapeutics

XACDURO (sulbactam + durlobactam) is an intravenous antibiotic developed by Innoviva Specialty Therapeutics (a subsidiary of Innoviva). It combines sulbactam, a B-lactam antibacterial, with durlobactam, a B-lactamase inhibitor designed to protect sulbactam from degradation by resistant enzymes.

XACDURO was approved by the US FDA in May 2023 for the treatment of hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) caused by susceptible Acinetobacter baumannii-calcoaceticus complex in adults.

Pneumonia Emerging Drugs

Tosatoxumab (AR-301): Aridis Pharmaceuticals

AR-301 (tosatoxumab) is a fully human IgG1 monoclonal antibody that selectively targets Staphylococcus aureus alpha-toxin, a key virulence factor produced by both methicillin-resistant (MRSA) and methicillin-sensitive (MSSA) strains. By neutralizing alpha-toxin, AR-301 helps prevent toxin-mediated damage to host tissues and preserves immune cell function. Its mechanism of action is independent of the bacterium's antibiotic resistance profile, enabling activity against infections caused by both MRSA and MSSA strains.

The US FDA granted Qualified Infectious Disease Product (QIDP) designation to Tosatoxumab (AR-301) in July 2023 to support and accelerate its clinical development as an adjunctive therapy for Staphylococcus aureus pneumonia.

Top-line data from the first of two planned global Phase III trials evaluating a single dose of AR-301 as an adjunct to standard-of-care antibiotics in VAP caused by Staphylococcus aureus were reported in September 2023. AR-301 was generally well tolerated in the full analysis set (FAS), and in the microbiologically confirmed population, an 11.3% numerical improvement in clinical cure rate at Day 21 was observed, although the result did not reach statistical significance

AON-D21: Aptarion Biotech

AON-D21 is an investigational L-aptamer (a synthetic nucleic acid-based therapeutic) designed to selectively neutralize complement factor C5a, a key inflammatory mediator implicated in excessive immune activation that can lead to severe inflammatory damage, multi-organ dysfunction, and mortality; preclinical studies have demonstrated its efficacy in translational models of pneumonia and sepsis, as well as in lung cancer, particularly in combination with immune checkpoint inhibitors highlighting the broader therapeutic potential of C5a modulation across immune-mediated diseases.

In January 2026, AON-D21 completed patient enrollment in the international Phase II ADCAP trial assessing its efficacy and safety in patients with severe community-acquired pneumonia.

In March 2025, AON-D21 received clearance of its US Investigational New Drug (IND) application, along with approval to expand the ongoing Phase II ADCAP trial to enroll up to 150 patients. The extension is intended to further evaluate the safety, tolerability, and efficacy of AON-D21 in patients with severe community-acquired pneumonia, supporting the generation of more robust clinical data to inform subsequent development stages.

Pneumonia Market Outlook

The Pneumonia market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Pneumonia market trends by analyzing the impact of current Pneumonia therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of Pneumonia market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Pneumonia market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Pneumonia market in 7MM is expected to witness a major change in the study period 2022-2036.

Pneumonia Drugs Uptake

This section focuses on the rate of uptake of the potential Pneumonia drugs recently launched in the Pneumonia market or expected to get launched in the market during the study period 2022-2036. The analysis covers Pneumonia market uptake by drugs; patient uptake by therapies; and sales of each drug.

Pneumonia Drugs Uptake helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allow the comparison of the drugs on the basis of Pneumonia market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Pneumonia Pipeline Development Activities

The Pneumonia report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Pneumonia key players involved in developing targeted therapeutics.

Pipeline Development Activities

The Pneumonia report covers the detailed information of collaborations, acquisition, and merger, licensing, patent details, and other information for Pneumonia emerging therapies.

Reimbursement Scenario in Pneumonia

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current Pneumonia market trends, we take KOLs and SMEs ' opinion working in the Pneumonia domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Pneumonia market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Pneumonia Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Pneumonia Market Report

• The report covers the descriptive overview of Pneumonia, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
• Comprehensive insight has been provided into the Pneumonia epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for Pneumonia is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of the Pneumonia market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Pneumonia market

Pneumonia Market Report Highlights

• In the coming years, the Pneumonia market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The companies and academics are working to assess challenges and seek opportunities that could influence Pneumonia R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
• Major players are involved in developing therapies for Pneumonia. The launch of emerging therapies will significantly impact the Pneumonia market
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Pneumonia
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Pneumonia Report Insights

• Pneumonia Patient Population
• Pneumonia Therapeutic Approaches
• Pneumonia Pipeline Analysis
• Pneumonia Market Size and Trends
• Pneumonia Market Opportunities
• Impact of upcoming Pneumonia Therapies

Pneumonia Report Key Strengths

• 11 Years Forecast
• 7MM Coverage
• Pneumonia Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Pneumonia Drugs Uptake

Pneumonia Report Assessment

• Current Pneumonia Treatment Practices
• PneumoniaUnmet Needs
• Pneumonia Pipeline Product Profiles
• Pneumonia Market Attractiveness
• Pneumonia Market Drivers
• Pneumonia Market Barriers

Key Questions Answered In The Pneumonia Market Report

Pneumonia Market Insights:

• What was the Pneumonia drug class share (%) distribution in 2022 and how it would look like in 2036?
• What would be the Pneumonia total market size as well as market size by therapies across the 7MM during the forecast period (2026-2036)?
• What are the key findings pertaining to the market across 7MM and which country will have the largest Pneumonia market size during the forecast period (2026-2036)?
• At what CAGR, the Pneumonia market is expected to grow by 7MM during the forecast period (2026-2036)?
• What would be the Pneumonia market outlook across the 7MM during the forecast period (2026-2036)?
• What would be the Pneumonia market growth till 2036, and what will be the resultant market Size in the year 2036?
• How would the unmet needs affect the market dynamics and subsequent analysis of the associated trends?

Pneumonia Epidemiology Insights:

• What are the disease risk, burden, and regional/ethnic differences of the Pneumonia?
• What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What is the historical Pneumonia patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What would be the forecasted patient pool of Pneumonia in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• Where will be the growth opportunities in the 7MM with respect to the patient population pertaining to Pneumonia?
• Out of all 7MM countries, which country would have the highest prevalent population of Pneumonia during the forecast period (2026-2036)?
• At what CAGR the patient population is expected to grow in 7MM during the forecast period (2026-2036)?

Current Pneumonia Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current options for the Pneumonia treatment in addition to the approved therapies?
• What are the current treatment guidelines for the treatment of Pneumonia in the USA, Europe, and Japan?
• What are the Pneumonia marketed drugs and their respective MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
• How many companies are developing therapies for the treatment of Pneumonia?
• How many therapies are in-development by each company for Pneumonia treatment?
• How many are emerging therapies in mid-stage, and late stage of development for Pneumonia treatment?
• What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Pneumonia therapies?
• What are the recent novel therapies, targets, mechanisms of action and technologies being developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Pneumonia and their status?
• What are the current challenges faced in drug development?
• What are the key designations that have been granted for the emerging therapies for Pneumonia?
• What are the global historical and forecasted market of Pneumonia?

Reasons to buy Pneumonia Market Report

• The report will help in developing business strategies by understanding trends shaping and driving the Pneumonia market
• To understand the future market competition in the Pneumonia market and Insightful review of the key market drivers and barriers
• Organize sales and marketing efforts by identifying the best opportunities for Pneumonia in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for Pneumonia market
• To understand the future market competition in the Pneumonia market